Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com
Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

SWIFT-seq was able to successfully capture CTCs in 90% of patients with MGUS, SMM, and MM. | Image credit: luchschenF - stock.adobe.com
Novel Blood Test Could Transform Multiple Myeloma Diagnosis, Monitoring

August 23rd 2025

Whether KRd‐based quadruplets will redefine the frontline standard now hinges on proving they can deliver deeper, longer‐lasting remissions without compromising safety. | Image credit: Dzmitry - stock.adobe.com
Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone

August 21st 2025

Myeloma cells | Image: ASH image bank
On the Path to Greater Precision in Treating Multiple Myeloma

August 18th 2025

The model has the potential to boost early detection of MM and contribute to a paradigm shift in the treatment of MM. | Image credit: shidlovski - stock.adobe.com
Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

August 13th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
September 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 17th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
September 17th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
September 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
September 17th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

RWE Decision-Making Barriers
April 12th 2022

RWE Decision-Making Barriers

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.
Incorporating RWE in MM Decision-Making
April 12th 2022

Incorporating RWE in MM Decision-Making

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.
a magnifying glass over a report with a 3D graph on it
April 11th 2022

New Minimal Residual Disease Assessment Could Detect Disease Progression Earlier in MM

Skylar Jeremias
Flow–minimal residual disease (MRD) assessment in patients with multiple myeloma (MM) was found to be a good tool for early detection of MRD and could aid providers in treatment decision-making.
Image of health care costs
April 9th 2022

Study Finds Potential Association Between Allostatic Load, Worse Overall Survival in MM

Rose McNulty
A recent study aimed to identify associations between socioeconomic status, allostatic load, and clinical trial end points in patients with multiple myeloma (MM).
The Value of RWE in MM
April 5th 2022

The Value of RWE in MM

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.
MM and Real-World Evidence
April 5th 2022

MM and Real-World Evidence

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.
Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says
April 2nd 2022

Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says

Mary Caffrey
Whether a patient is refractory to initial treatment dictates the future course of care.
Image of scientific research
March 30th 2022

Review Examines Growing Treatment Options for Heavily Refractory MM

Jared Kaltwasser
Relapse remains a daunting reality in multiple myeloma, but clinicians have more tools to work with to fight the disease.
MM and the Limitations of RCT Data
March 29th 2022

MM and the Limitations of RCT Data

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.
Decision Support Tools for MM
March 29th 2022

Decision Support Tools for MM

A panel of experts elaborate on the decision support tools that are utilized by physicians to give patients high-value regimens.
Scale to measure weight
March 25th 2022

Obesity Increases Risk of MM Precursor, While Weight Loss Indicates Risk of Cancer Diagnosis

Laura Joszt, MA
Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.
MM Healthcare Resource Utilization
March 22nd 2022

MM Healthcare Resource Utilization

The panel discusses the data used to evaluate healthcare resources for MM therapy, as well as economic burden.
MM From the Payers’ Perspective
March 22nd 2022

MM From the Payers’ Perspective

Dr Beveridge provides a payer’s perspective on the available regimens for MM treatment.
man holding a tablet that is projecting different graphs
March 22nd 2022

New Risk Prediction Model for MM Outcomes Found Easy to Use, Implement in Clinical Practice

Skylar Jeremias
A new frailty-based outcome prediction model for multiple myeloma (MM) was found to be an easy-to-use tool in clinical practice and produced valid results based on a large real world cohort of patients with a new MM diagnosis, according to a recent study.
dna surrounded by data
March 18th 2022

Multi-Tiered Risk Stratification Model for MM May Perform Better Than Standard Systems

Skylar Jeremias
Risk stratification is a difficult process for multiple myeloma (MM), and authors concluded that their multi-tiered model may provide a greater risk assessment benefit than standard stratification systems.
MM and Regimens for First- and Second-Line Treatment
March 15th 2022

MM and Regimens for First- and Second-Line Treatment

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.
A Multiple Myeloma Overview
March 15th 2022

A Multiple Myeloma Overview

Muhamed Baljević, MD, FACP, provides a background of multiple myeloma (MM) within the past five years and the main treatment options.
a bottle of pils with a clipart image of an orangle slice and the words "vitamin D and multiple myeloma" written
March 11th 2022

Addressing Low Vitamin D Levels May Reduce Risk of Peripheral Neuropathy in MM

Skylar Jeremias
Researchers found that low levels of vitamin D and the prevalence of peripheral neuropathy were common in patients with multiple myeloma, suggesting that addressing the former could help prevent the latter.
doctor comforting patient in a hospital bed
March 8th 2022

Study Finds Decorin May Have Protective Effect in Multiple Myeloma

Skylar Jeremias
Decorin, a highly conserved, class 1 small leucine-rich repeat proteoglycan expressed in the extracellular matrix, may have a protective effect in a subset of patients with multiple myeloma, investigators concluded.
xray showing knee bones
March 4th 2022

More Early Palliative Care May Be Needed to Individualize Pain Management in MM

Skylar Jeremias
Investigators concluded that early palliative care may be needed for more patients with multiple myeloma (MM) as pain can manifest in different ways and severity levels depending on disease state, suggesting that a more individualized approach is critical for pain management.
man grabbing at head and neck in pain
February 28th 2022

Study on Types of Pain in MM Reveals Communication Inadequacies Between Physicians, Patients

Skylar Jeremias
A study showed that patients with multiple myeloma (MM) deal with physical, social, and emotional pain and that physicians did not fully comprehend the extent to which patients experienced pain, suggesting improved communication between parties is warranted.
old woman exercising
February 25th 2022

Study Highlights Unmet Exercise Needs Among Patients With MM

Skylar Jeremias
Health care providers need to foster a greater push for physical activity as a part of survivorship care for patients with multiple myeloma (MM), investigators concluded after finding that only 25% of patients were active.
man holding a tablet projecting an image of a brain made up of computer chips
February 22nd 2022

Review Outlines Unmet Need for Digital Health in Elderly Patients With MM

Skylar Jeremias
Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.
dna in a test tube
February 16th 2022

Cancer-Related Micro-RNAs May Serve as MM Bone Disease Biomarkers

Skylar Jeremias
Two cancer-related micro-RNAs could serve as prognostic biomarkers for multiple myeloma bone disease as lower levels were associated with lower overall survival rates, investigators concluded.
old woman's eye
February 9th 2022

Clinical, Economic Burden of Corneal Adverse Events in MM Is Low Compared With Total All-Cause Costs

Skylar Jeremias
Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.
old woman sitting in chair
February 4th 2022

Risk of Early Death Remains High Among Older Patients With MM

Skylar Jeremias
Early mortality rates for patients with multiple myeloma (MM) have significantly decreased over the last 20 years; however, more efforts are needed for older patients, who still experience high rates.
clip art images representing different aspects of healthcare surrounding the world "coronavirus"
February 1st 2022

COVID-19 Led to Delayed Diagnoses, Increased Infection Risk, Lower Survival Rates in MM

Skylar Jeremias
A large international real-world analysis revealed the extent to which the COVID-19 pandemic has impacted the global population of patients with multiple myeloma (MM) and the ability for providers to help patients manage the condition.
a IV containing chemotherapy treatment next to a picture of a cancer cell
January 28th 2022

Study: Adrenal Insufficiency Found in Some MM Patients on Corticosteroid-Based Chemotherapy

Skylar Jeremias
About half of all patients with multiple myeloma (MM) receiving corticosteroid-based chemotherapy were found to have adrenal insufficiency (AI), while identifying suspicious symptoms of AI may be a key component to its detection in this population.
Doctor's coat
January 19th 2022

Screening Initiative Identifies Those at Highest Risk of Developing MM

Gianna Melillo
Research presented at the 2021 American Society of Hematology Annual Meeting and Exposition highlights efforts in screening for multiple myeloma (MM).
pill graphic
January 17th 2022

Updated GRIFFIN Data Show Safety, Efficacy of Adding Daratumumab in NDMM Maintenance

Mary Caffrey
Can daratumumab be taken safely as a maintenance therapy? Will quadruplet therapy become more common in the treatment of newly diagnosed multiple myeloma (NDMM)?
<1
...
78910111213>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo